Zacks Investment Research
10 Sept 2026, 18:40 UTC · 14h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA has granted Fast Track designation to Liquidia Corporation's Yutrepia (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). — Fast Track designation expedites the regulatory review process and increases the probability of faster market entry for a new indication.
+0.60Liquidia plans to initiate the RE-WARM phase IIa study in October 2026 to evaluate Yutrepia's safety and efficacy in treating SSc-RP. — The commencement of clinical trials is a necessary milestone for commercialization, though phase IIa is an early-stage catalyst.
+0.30Liquidia is seeking to expand Yutrepia's growth opportunity into several additional indications, including PH-COPD, IPF, and PPF. — Expanding the total addressable market (TAM) for an existing approved drug creates long-term valuation upside.
+0.20Which stocks this story touches
Continue reading
5 related stories
Search tags
The FDA granted Fast Track designation for its drug Yutrepia to treat Raynaud's phenomenon, expanding growth opportunities.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
19h ago
